



A Global Hub for Life Sciences

London & UK



Contents

- 4** A message from MedCity
- 6** A message from British Embassy Tokyo
- 8** UK delegation at BioJapan
- 10** The UK's academic and research capability
- 12** Why choose London and the UK?

Our Delegation

- 16** MedCity/London & Partners
- 17** Richmond Pharmacology
- 18** Queen Mary University of London
- 19** University College London
- 20** National Institute for Health and Care Research
- 21** Department for Business, Innovation, Science and Trade
- 22** BIST Japan Trade Mission
- 24** Grow London Global Trade Mission

A message from MedCity

We are delighted to be attending BioJapan 2026. This is the tenth year we have joined one of Asia's leading bioindustry partnering events, a testament to the strong and enduring ties between London and Japan's life sciences sectors. This year, we look forward to renewing existing relationships, building new partnerships and exploring opportunities for deeper collaboration between our two innovation ecosystems.

In London, we continue to strengthen the city's position as a global hub for life sciences by bringing together industry, academia, investors and the public sector to drive economic growth, boost innovation and encourage collaboration. Examples of this impact over the past year include approval for the £1 billion expansion of the London Cancer Hub in south London, a £3 billion development announced by SC1 London, and Isomorphic Labs raising almost half a billion pounds to accelerate AI-powered drug discovery. Autolus, a University College London spinout, also secured FDA approval for its CAR-T leukaemia therapy, Aucatzyl, while London-based biotech company Verdiva Bio completed a £327 million financing round.

Our work also includes organising and hosting London Life Sciences Week, alongside our partners at the BioIndustry Association (BIA). The event brings together investors, policymakers, business leaders and innovators to showcase breakthrough discoveries, foster investment opportunities and strengthen connections across the global life sciences community.

London's long history, culture and scientific heritage have helped create one of the world's most dynamic life sciences ecosystems. The sector continues to benefit from strong government support, including a commitment of £520 million for UK life sciences manufacturing and a landmark £400 million public-private investment to enhance

clinical trial capabilities. The UK remains one of Europe's leading destinations for life sciences investment and growth. London-based life sciences companies raised £2.2 billion in venture capital investment in 2025 and have already raised more than £2.8 billion in 2026.

To support future growth, London has one of Europe's largest life sciences infrastructure development pipelines, with more than 2.7 million square feet of dedicated laboratory and innovation space under construction. This builds on the city's world-renowned research ecosystem, which includes the Francis Crick Institute and leading universities such as Imperial College London, University College London, King's College London and Queen Mary University of London, alongside national initiatives including the 100,000 Genomes Project and the new Health Data Research Service.

Japan is a global leader in life sciences innovation, advanced healthcare technologies and translational research. The UK and Japan share a long-standing commitment to scientific excellence and international partnership, with increasing collaboration across areas such as advanced therapeutics, regenerative medicine, AI-enabled drug discovery and precision medicine. BioJapan provides an important platform to strengthen these connections, explore new opportunities and translate shared ambition into lasting impact.

ごあいさつ

今年もBioJapan 2026に参加できることを、大変うれしく思っています。アジアを代表するバイオ産業のパートナーリングイベントであるBioJapanへの参加は、今回で10年目となります。これは、ロンドンと日本のライフサイエンス分野における強い結び付きを物語るものです。今年は関係をさらに深めるとともに、新たなパートナーシップを築き、双方のイノベーション・エコシステムの連携をいっそう発展させる機会となることを楽しみにしています。私たちは、産業界、学术界、投資家、公共部門をつなぎ、経済成長やイノベーションを促進するとともに、新たな連携を生み出すことで、ロンドンがライフサイエンス分野における世界的な拠点としての地位をさらに高められるよう取り組んでいます。

この1年も、大きな進展が相次ぎました。具体的には、ロンドン南部の「London Cancer Hub」において10億ポンド規模の拡張計画が承認されたほか、SC1 Londonによる30億ポンド規模の開発計画が発表されました。また、Isomorphic Labsは、AIを活用した創業を加速するため、約5億ポンドを調達しています。さらに、ユニバーシティ・カレッジ・ロンドンのスピンアウト企業であるAutolusは、CAR-T白血病治療薬「Aucatzyl」で米国食品医薬品局（FDA）の承認を取得しました。加えて、ロンドンを拠点とするバイオテクノロジー企業Verdiva Bioも、3億2,700万ポンドの資金調達を実現しています。

私たちは、BioIndustry Association (BIA) と連携し、「ロンドン・ライフサイエンス・ウィーク」の企画・開催にも取り組んでいます。このイベントは、投資家、政策立案者、企業のリーダー、イノベーターが集い、画期的な研究成果を共有し、新たな投資機会を創出するとともに、世界のライフサイエンス関係者が交流を深める場となっています。

ロンドンは、豊かな歴史と多様な文化、そして長年にわたって培われてきた科学の伝統を背景に、世界有数のライフサイエンス・エコシステムを築いてきました。その成長を支えているのが、ライフサイエンス製造業への5億2,000万ポンドの支援方針や、臨床試験体制の強化に向けた4億ポンドの官民共同投資など、英国政府によるさまざまな支援です。英国は、ライフサイエンス分野の投資と事業成長を支える、欧州有数の市場です。ロンドンを拠点とするライフサイエンス企業は、2025年にベンチャー

キャピタルから22億米ドルを調達しており、2026年もすでに28億米ドルを超える資金を調達しています。

今後の成長を支えるため、ロンドンでは欧州有数のライフサイエンス関連施設の開発プロジェクトが進んでおり、現在建設中の研究施設やイノベーション関連施設の延床面積は270万平方フィートを超えます。こうした成長を支えているのが、世界的に高く評価されるロンドンの研究エコシステムです。フランス・クリック研究所をはじめ、インペリアル・カレッジ・ロンドン、ユニバーシティ・カレッジ・ロンドン、キングス・カレッジ・ロンドン、クイーン・メアリー・ユニバーシティ・オブ・ロンドンなどの研究機関に加え、10万人ゲノムプロジェクトや新たな医療データ研究サービスといった国家的な取り組みが、その発展を後押ししています。

日本は、ライフサイエンス分野におけるイノベーションや先進医療技術、橋渡し研究（トランスレーショナルリサーチ）において世界をけん引しています。英国と日本は、卓越した科学研究と国際的な連携を重視するという共通の姿勢を持っており、先進的治療法、再生医療、AIを活用した創業、プレジジョン・メディシンなどの分野で連携を深めています。BioJapanは、こうした連携をさらに深め、新たな可能性を探り、共通のビジョンを持続的な成果へとつなげる重要な場となっています。ぜひBioJapanの会場で、MedCityのメンバーや英国代表团にお声がけください。イノベーション、協業、成長につながる可能性について、皆さまとお話できることを楽しみにしています。

A message from the British Embassy Tokyo

I am delighted to welcome you to this year's UK–Japan Life Sciences Week and to meet the UK delegation at BioJapan 2026.

The United Kingdom is home to one of the world's leading life sciences sectors, combining world-class research, a strong clinical development environment, and pioneering companies working at the forefront of healthcare innovation.

At BioJapan this year we have an incredible group of UK life sciences companies and innovators whose work spans areas such as advanced therapeutics, neuroscience, precision medicine, and emerging biotechnology. Their presence reflects not only the breadth of UK clinical and scientific excellence, but also the qualities that have made the UK a trusted partner in advancing healthcare, improving patient outcomes, and bringing new solutions to those who need them most.

The UK Government's Modern Industrial Strategy and Life Sciences Sector Plan, launched last year, set out a long-term vision to strengthen the UK's position as a global leader in life sciences. Backed by more than £2 billion of government funding, they aim to accelerate research and development, strengthen clinical research and manufacturing capabilities, and create an environment in which scientific discoveries can be translated more rapidly

into real-world impact.

More recently, Prime Minister Takaichi's visit to the United Kingdom in June 2026 saw the announcement of the UK–Japan Frontier Technology Partnership. Among its areas of cooperation, the partnership includes a shared commitment to deepen collaboration in healthcare and life sciences, including promoting research and development while strengthening our capabilities as globally connected, world-leading hubs for drug discovery. By bringing together scientific excellence, industrial capability, and international collaboration, both countries are well positioned to accelerate the development of the next generation of healthcare innovations.

We look forward to building on this momentum and to shaping a healthier future together, and my team and I welcome any interest you may have in collaboration or partnership opportunities.

We look forward to working with you to shape a healthier, more innovative future together, and I and my team welcome any interest you might have in collaboration or partnerships.

グレッグ・ガードナー

駐日英国大使館
貿易・対英投資ダイレクター
公使参事官(北東アジア地域貿易担当)



Greg Gardner
Director of Trade &
Investment Japan/Deputy
Trade Commissioner
North-East Asia

本年も「UK-Japan Life Sciences Event Week」および「BioJapan 2026」において、英国代表团をお迎えし、日本の皆さまにご紹介できることを大変光栄に思います。

英国は、世界をリードするライフサイエンス・エコシステムを有しており、卓越した研究力、先進的な企業群、そして研究成果を迅速に実用化へとつなげる環境を強みとしています。基礎研究から臨床開発、製造、商業化に至るまで、一貫した産業基盤を備え、医療イノベーションを世界へ届ける重要な役割を果たしています。

本年のBioJapanには、英国を代表する企業、研究機関、大学が参加し、先進医療、神経科学、プレジジョン・メディシン、次世代バイオテクノロジーなど、幅広い分野における最新の取組をご紹介します。英国は、医療の進歩と患者アウトカムの向上に貢献する信頼できるグローバル・パートナーとして、国際的に高い評価を得ています。

英国政府は昨年、「Modern Industrial Strategy (新たな産業戦略)」および「Life Sciences Sector Plan (ライフサイエンス産業計画)」を発表し、ライフサイエンス分野における世界的リーダーとしての英国の地位をさらに強化するための長期ビジョンを示しました。20億ポンドを超える政府投資を背景に、研究開発の加速、臨床研究および製造能力の強化、そして科学的発見をより迅速に社会実装へとつなげる環境整備を推進しています。

さらに、2026年6月に英国で開催された日英首脳会談では、「UK-Japan Frontier Technology Partnership (英国・日本フロンティア・テクノロジー・パートナーシップ)」の創設が発表されました。このパートナーシップでは、医療・ライフサイエンス分野における協力強化が重要な柱の一つとして位置付けられており、研究開発の促進に加え、創薬分野における世界有数の拠点としての両国の能力向上に共同で取り組むことが表明されています。

科学的卓越性、高度な産業基盤、そして国際連携の力を結集することで、英国と日本は次世代の医療イノベーションを共に創出する絶好の機会を迎えています。私たちは、この協力関係をさらに発展させ、より健康で持続可能な未来の実現に貢献していきたいと考えています。

BioJapan 2026が新たなパートナーシップやビジネス、そして研究協力の創出につながることを心より願っています。英国との協業やパートナーシップにご関心をお持ちの方は、ぜひお気軽に私どもまでお声がけください。

London at BioJapan

Visit the London & UK delegations at stand number C-24, and meet with:

- MedCity, the cluster organisation for London's world-leading life science ecosystem.
- Leading scientists from London's world-renowned universities and research institutes.
- Experts on collaboration and commercialisation in the UK life science ecosystem.
- UK government representatives.
- A delegation of innovative engineering biology companies from across the UK.



ブースのご案内

私たちのブースでは、以下のロンドン・英国代表団のメンバーが皆さまのご来場をお待ちしています。

- 世界有数のライフサイエンス・エコシステムを擁するロンドンのクラスター組織「MedCity」
- ロンドンの世界的に有名な大学や研究機関に所属するトップレベルの研究者
- 英国のライフサイエンス分野における連携や事業化の専門家
- 英国政府関係者
- 英国各地の革新的なエンジニアリング・バイオロジー企業の代表団



The UK's academic and research capability

The UK's research capability is synonymous with excellence and innovation. This capability underpins social and economic progress and improves lives every day.

The UK's universities have an undisputed track record of world-changing research, discoveries and inventions. The UK has four universities in the global top 10, with Imperial now ranked as the joint second best university in the world.

We have a long history of collaboration with international partners. The combined expertise of Kyoto's Shinya Yamanaka and Cambridge's John Gurdon led to one of the greatest breakthroughs in stem cell research: induced pluripotent stem cells, earning them the Nobel Prize in 2012.

As well as high-profile success stories, UK higher education institutions provide the skills and training to develop and progress the life science innovations of tomorrow, ensuring the sector can continue to draw from an excellent pool of talent. Launched in 2018, the Centres for Doctoral Training (CDTs) set up by UK universities, either individually or in partnership, will train more than 4,000 PhD students over nine years in specific research areas.

Our universities also bolster the life science ecosystem by establishing and supporting spinout companies. Collaboration is playing a major role, with some of the most ambitious companies born from more than one parent institution. Through the establishment of Knowledge Transfer Partnerships, centres for business support and institution-specific investment bodies, UK universities are translating pioneering intellectual property developed in their laboratories into commercially viable products.



Top 20 universities*

Overall ranking for the best universities in the world in 2027:

Imperial	=2
University of Oxford	4
University of Cambridge	6
UCL	=8

6 in the top 20 universities for 'Life Sciences and Medicine' in 2026:

University of Oxford	2
University of Cambridge	5
Imperial	=6
UCL	=6
King's College London	9
The University of Edinburgh	20

3 in the top 10 universities for 'Engineering and Technology' in 2026:

University of Oxford	4
University of Cambridge	5
Imperial	7

3 in the top 25 universities for 'Data Science and Artificial Intelligence' in 2026:

University of Oxford	=6
Imperial	=15
UCL	22

Number of students**

- 2,733,780 students studying in the UK in 2024/25 (both UK and International)

Life Sciences

- 456,115 total number of life sciences students
- 110,365 taught postgraduate life sciences students
- 16,925 life sciences students in post graduate research

Centres for Doctoral Training (CDTs)***

More than 4,000 doctoral students will be trained over the course of nine years at 65 CDTs across the UK. The CDT programme has received:

- £479m funding from EPSRC, including £16m additional UK Research and Innovation (UKRI) funding in quantum technologies.
- More than £7m from the Biotechnology and Biological Sciences Research Council (BBSRC).
- £16m by the Ministry of Defence (MoD).
- £169m by UK universities.
- £420m in financial and in-kind support from business, public sector, and charity partners.

This investment includes an additional £135m from EPSRC for CDTs to start in 2025.

Who is with us at BioJapan?



NIHR | National Institute for Health and Care Research

richmond

* QS World University Rankings 2026/2027

** HESA Student Record, 2024/25.

*** <https://www.ukri.org/what-we-do/developing-people-and-skills/epsrc/studentships/centres-for-doctoral-training/>

Why choose London and the UK?

The UK is home to one of the world's most productive and influential scientific communities. It has contributed to more than 80 Nobel Prize-winning discoveries and continues to play a leading role in advancing biomedical science. London alone is home to three globally recognised universities with outstanding strengths in life sciences and medicine: Imperial College London, University College London and King's College London.

For centuries, the UK has been a centre of scientific discovery and medical innovation. Institutions such as the Universities of Oxford and Cambridge, Imperial College London, King's College London, University College London and Queen Mary University of London continue to drive breakthrough research, translation and commercialisation. Together, they form a collaborative ecosystem that combines academic excellence, entrepreneurial ambition and strong industry partnerships, providing a powerful foundation for life sciences innovation.

- The UK attracted more than £1.2 billion in life sciences greenfield foreign direct investment in 2025, generating around 4,235 jobs across 54 projects.
- UK life sciences companies raised \$4 billion in venture capital financing in 2025, with a further \$3.8 billion raised during the first half of 2026.
- In 2025, London's life sciences companies raised approximately \$2.2 billion in venture capital investment, more than Paris, Berlin and Stockholm combined, and more than Shanghai, Tokyo and Singapore combined. London companies have already raised more than \$2.8 billion in 2026.
- The UK generated 10.8% of global medical sciences citations in 2024, behind only the United States and China.
- The London–Oxford–Cambridge “Golden Triangle” is widely recognised as one of the world's leading life sciences clusters and is

often ranked second only to Greater Boston/Cambridge, Massachusetts.

- In 2023, the UK's government budget allocation for health R&D was 0.12% of GDP, the fourth highest among comparator countries, behind only the United States, Denmark and Norway.
- With more than 2.7 million square feet of life sciences space under construction, London has one of Europe's largest development pipelines for life sciences infrastructure.
- The UK continues to support bold scientific innovation through initiatives such as the 100,000 Genomes Project, the Health Data Research Service and the Francis Crick Institute.

The National Health Service (NHS) is the world's largest publicly funded integrated healthcare system, treating around one million patients every day. Its scale, rich health data resources and extensive clinical research infrastructure make it an attractive environment for developing, testing and evaluating new healthcare innovations. The UK has also secured a landmark £400 million public-private investment to support faster patient access to cutting-edge treatments and strengthen clinical trials. Beyond research and innovation, the UK plays a leading role in addressing global health challenges, with universities, charities, researchers and businesses working together on issues ranging from antimicrobial resistance and dementia to neglected tropical diseases.



The UK's infrastructure for developing medicines and medical technologies is world-class. The National Institute for Health and Care Excellence (NICE) provides internationally respected health technology assessments, while the National Institute for Biological Standards and Control (NIBSC) plays a critical role in the development and supply of global biological standards. Alongside the Medicines and Healthcare products Regulatory Agency (MHRA), these organisations help create a supportive environment for innovation while ensuring the highest standards of quality, safety and effectiveness.

Together, these strengths make London and the UK one of the world's most attractive locations for life sciences innovation, investment and growth. Combining world-class science, entrepreneurial talent, deep pools of capital, a collaborative healthcare system and a globally connected business environment, the ecosystem offers exceptional opportunities for organisations looking to discover, develop and deliver the next generation of healthcare innovations. We look forward to exploring those opportunities with you at BioJapan 2026.

ロンドン・英国が持つ独自の強み

英国は、世界有数の研究力と影響力を誇る科学コミュニティを擁しています。これまでに80件を超えるノーベル賞受賞につながる発見を生み出し、現在もバイオメディカル分野の発展をリードしています。なかでもロンドンには、ライフサイエンスと医学の分野で世界的に高く評価される、インペリアル・カレッジ・ロンドン、ユニバーシティ・カレッジ・ロンドン、キングス・カレッジ・ロンドンがあります。

長年にわたり、英国は科学的発見と医療イノベーションをけん引してきました。オックスフォード大学やケンブリッジ大学をはじめ、インペリアル・カレッジ・ロンドン、キングス・カレッジ・ロンドン、ユニバーシティ・カレッジ・ロンドン、クイーン・メアリー・ユニバーシティ・オブ・ロンドンなどの研究機関は、画期的な研究成果を生み出すとともに、その実用化や事業化も推進しています。これらの研究機関は、卓越した研究力、起業家精神、産業界との緊密なパートナーシップを結び付けるエコシステムを形成し、ライフサイエンス分野のイノベーションを支えています。

- 英国における、海外企業によるライフサイエンス分野への新規進出・拠点開設投資は、2025年に12億ポンドを超え、54件のプロジェクトを通じて4,235人の雇用が創出されました。
- 2025年、英国のライフサイエンス企業は、ベンチャーキャピタルから40億米ドルの資金を調達しました。さらに、2026年上半年だけでも38億米ドルを調達しています。
- ロンドンのライフサイエンス企業は、2025年にベンチャーキャピタルから約22億米ドルの資金を調達しました。この額は、パリ・ベルリン・ストックホルムの合計、および上海・東京・シンガポールの合計をそれぞれ上回っています。2026年の資金調達額は、すでに28億米ドルを超えました。
- 2024年、世界の医学分野の論文引用数の10.8%を英国が占め、米国、中国に次ぐ世界第3位となりました。
- ロンドン・オックスフォード・ケンブリッジを結ぶ「ゴールデン・トライアングル」は、世界を代表するライフサイエンス・クラスターの一つとして

広く知られており、米国マサチューセッツ州のボストン／ケンブリッジ地域に次ぐ存在として評価されています。

- 2023年、英国政府による医療分野の研究開発予算はGDP比0.12%となり、主要比較国の中では、米国、デンマーク、ノルウェーに次ぐ第4位となりました。
- ロンドンでは現在、270万平方フィートを超えるライフサイエンス関連施設の建設が進んでおり、その開発規模は欧州最大級となっています。
- 英国は、10万人ゲノムプロジェクト、医療データ研究サービス、フランシス・クリック研究所など、先進的な科学研究を支える国家的な取り組みや研究基盤を整備しています。

英国の国民保健サービス (NHS) は、公的資金によって運営される世界最大級の統合型医療システムです。毎日約100万人の患者に医療を提供しており、その規模、豊富な医療データ、充実した臨床研究基盤は、新たな医療技術を開発・検証・評価するための優れた環境を生み出しています。また英国では、患者が最先端の治療法をより早く受けられる環境づくりと臨床試験体制の強化に向け、4億ポンド規模の官民共同投資を実現しました。さらに、研究やイノベーションだけでなく、世界的な健康課題への対応においても英国は重要な役割を果たしており、大学、慈善団体、研究者、企業が連携し、薬剤耐性や認知症、顧みられない熱帯病など、さまざまな課題の解決に取り組んでいます。

英国は、医薬品や医療技術の開発を支える世界トップクラスの基盤を備えています。英国国立医療技術評価機構 (NICE) は、世界的な指標となる医療技



術評価を提供しており、国立生物学標準管理研究所 (NIBSC) は、生物製剤の国際基準の策定と供給において重要な役割を担っています。さらに、英国医薬品・医療製品規制庁 (MHRA) をはじめとするこれらの機関が、イノベーションを支えるとともに、品質、安全性、有効性の確保に取り組んでいます。

こうした強みにより、ロンドンと英国は、ライフサイエンス分野におけるイノベーション、投資、成長を支え

る世界有数の拠点となっています。世界トップクラスの科学力、起業家人材、豊富な投資資金、連携の進んだ医療システム、そしてグローバルにつながるビジネス環境を兼ね備えたこのエコシステムは、次世代の医療イノベーションの創出から開発・実用化までを目指す組織にとって、絶好の環境です。BioJapan 2026 で、皆さまと新たな可能性について意見を交わせることを楽しみにしています。



Janet Coyle CBE
Managing Director, Business Growth

jcoyle@londonandpartners.com



Wael Muselmani PhD
Senior Investment Manager -
Life Sciences

waelmuselmani@londonandpartners.com



Rikesh Patel
Senior Trade Manager, Life Sciences

rikpatel@londonandpartners.com

MedCity is part of the London & Partners family. It promotes the benefits of London as a place to locate and grow life science businesses and works with life science companies of all sizes to help them access the support they need to grow and thrive.

MedCity assists life science companies to identify and utilise opportunities within London's life science and healthcare landscape. It fosters collaborations between biotech, medtech and pharma companies and the capital's life science ecosystem to supercharge innovation, drive inward

investment and build skills and talent across the sector in the UK.

Working in close partnership with London's world-leading universities and national ecosystem stakeholders, MedCity creates powerful networks and partnerships to fast-track research and development to generate innovation.

As life science experts, MedCity also facilitates the development of life science space in London to support the growth of research-intensive businesses.



Dr Jorg Taubel
Executive Chairman and Co-Founder

eo@richmondpharmacology.com



Dr Ulrike Lorch
Chief Operating Officer and CoFounder

eo@richmondpharmacology.com



Dr Daniel Chapple
Commercial Director

d.chapple@richmondpharmacology.com



Stephen Wilkinson
Business Development Manager

s.wilkinson@richmondpharmacology.com



Nobuo Ittetsu
Head of Japanese Business
Development & Recruitment

n.ittetsu@richmondpharmacology.com



Minoru Takada
Japanese Business Development
Executive

m.takada@richmondpharmacology.com

Founded in 2001, Richmond Pharmacology is a leading Contract Research Organisation (CRO) with a strong heritage in first-in-human and adaptive clinical trials. The company has conducted around 20% of all UK Phase I studies and delivered landmark research, including the first lipid nanoparticle (LNP) CRISPR Cas-9 in vivo gene-editing drug trial in 2020.

Today, Richmond supports global pharmaceutical, biotech, and genetic

engineering partners, including top 10 pharma companies, in advancing next-generation therapies. With deep expertise in early-phase clinical development, Richmond helps accelerate the translation of innovative science into safe and effective medicines.

In 2020, Richmond established the Richmond Research Institute to expand scientific understanding of under-researched diseases and drive progress in areas of high unmet medical need.

X @RichmondPharma in Richmond Pharmacology

richmondpharmacology.com



Dr Jemma Trick
Senior Partnerships Manager (Health)

j.trick@qmul.ac.uk

Queen Mary University of London is one of the UK's leading research universities, committed to translating world-leading research into real-world impact.

We offer partners direct access to translational research and one of London's largest clinical academic communities. Our research spans a broad range of therapeutic areas, with strengths in five core priorities: oncology, dermatology, CVRM, inflammation, and health data science. This is underpinned by deep expertise across therapeutic development, diagnostics, precision medicine, and digital health, spanning the full clinical development pathway.

Our academics combine rigorous science with direct patient access through Barts



Dr Cecilia Boz
Business Development
Manager (Health)

c.boz@qmul.ac.uk

Health NHS Trust, one of the UK's largest and most diverse trusts, serving some of London's most ethnically diverse boroughs. This enables research with real population relevance and reach, including through our Genes and Health consortium, one of the world's largest community-based studies of genetics and health.

We partner flexibly, from sponsored research to multi-year strategic alliances, and our dedicated Business Development team works closely with industry to structure agreements that move fast without compromising scientific rigour.

We'd welcome the opportunity to explore how our capabilities align with your pipeline priorities.

 Queen Mary innovation

 qmul.ac.uk/research/collaborate-with-us/industry-collaboration



Catherine Perrodin

**Senior Business & Innovation
Manager**

c.perrodin@ucl.ac.uk

Founded in 1826, UCL was the first university in England to welcome students regardless of religion or background. Today, it is a global top 10 university and a leading centre for research, innovation and education, bringing together over 60,000 staff and students from 150 countries.

UCL connects disciplines, industries and cultures to address complex global challenges. Its researchers, clinicians, engineers and entrepreneurs work together to generate new knowledge and translate discoveries into real-world impact. More than half of UCL's research activity relates to health, supported by close collaboration with 6 partner hospitals.

Located at the heart of London's Knowledge Quarter, UCL is part of one of the world's most dynamic innovation ecosystems. Alongside internationally recognised strengths in neuroscience, oncology and regenerative



Polly Van Alstyne

Senior Innovation Networks Manager

p.vanalstyne@ucl.ac.uk

medicine, and capabilities in biotechnology, AI-enabled discovery and automation, UCL leads nearly half of the UK's academically sponsored advanced therapy clinical trials.

UCL takes a partnership-led approach to innovation, supporting businesses through access to world-leading academic and clinical expertise; strategic research collaborations; navigation of UK health and regulatory systems; and consortium-based funding opportunities. Through UCL Innovation and Enterprise, the university engages with organisations to translate research into practical solutions, and develop and commercialise pioneering technologies and therapeutics.

UCL's relationship with Japan dates back to 1863 and continues today through research, innovation and partnerships that deliver global societal benefits.

 @UCLEnterprise

 UCL Innovation and Enterprise

 ucl.ac.uk/engage



Dr. Maria Koufali
Life Sciences Industry Director

industry@nihr.ac.uk

The National Institute for Health and Care Research (NIHR) is the health and social care research arm of the nation. We work with UK-wide research networks and devolved administration partners to enable research across the UK.

The Industry Hub is our national delivery and accountability platform for commercial clinical trials. We provide commercial sponsors with a single point of entry and we coordinate commercial research delivery system-wide for every commercial trial. Through a reliable, high-performing operating model, we ensure that commercial sponsors experience a managed national research delivery environment.

Our end to end support spans:

- Feasibility and study placement - coordinated once, nationally
- Protocol and trial design support - including access to specialist expertise
- Costing, contracting and assurance - one national review process
- Site activation and study start-up sequencing - faster than national average set-up times
- Delivery performance management - including time-bound escalation and rapid issue resolution

Our support is free of charge, funded by the UK Government, and designed to make the UK a globally competitive destination for commercial clinical research by delivering outcomes that matter to sponsors:

- speed to activation
- recruitment reliability
- confidence in delivery
- reduced operational risk

 NIHR Industry Hub

 nihr.ac.uk/industry



Harriet Loos

Trade Counsellor, Department for Business, Innovation, Science and Trade, British Embassy Tokyo



Ayako Haraguchi

Head of Life Sciences – Trade, Department for Business, Innovation, Science and Trade, British Embassy, Tokyo



Aya Koike

Trade Adviser, Life Sciences, Department for Business, Innovation, Science and Trade, British Consulate-General, Osaka

The Department for Business, Innovation, Science and Trade (DBIST) supports economic growth by helping UK businesses succeed internationally, encouraging investment into the United Kingdom, and promoting innovation and scientific excellence. Through its global network, DBIST fosters trade, investment and collaboration that create opportunities for businesses and institutions in the UK and around the world.

In Japan, DBIST works closely with government, industry, research organisations and businesses to strengthen the UK–Japan relationship. We support UK companies seeking to export to Japan, help Japanese organisations explore opportunities in the UK, and facilitate collaboration in priority sectors including life sciences, clean energy, advanced manufacturing, technology and financial services.

Through strategic engagement, market intelligence and business support, DBIST helps organisations identify growth opportunities, build long-term partnerships and drive innovation, contributing to sustainable economic growth and shared prosperity.

駐日英国大使館および在大阪英国総領事館 ビジネス・イノベーション・科学・通商部は、日英間の貿易・投資に加え、科学技術・イノベーション分野における連携を推進しています。ライフサイエンス領域においては、企業、大学、研究機関等のパートナーシップ構築を支援するとともに、研究開発、商業化、投資促進および市場アクセスに関する取組を通じて、革新的な医療ソリューションの創出と社会実装に貢献しています。

X @UKinJapan

Instagram UKinJapan

LinkedIn uk-in-japan

Website gov.uk/world/organisations/british-embassy-tokyo

BIST Japan Trade Mission

The UK Department for Business, Innovation, Science and Trade is proud to lead a delegation of four pioneering life sciences companies to Japan. These innovators represent the cutting edge of biotechnology, sustainability, and advanced manufacturing—delivering solutions that address global challenges in health and the environment.

This mission is about building partnerships. We aim to connect UK expertise with Japanese industry leaders, research institutions, and investors. Together, we can unlock new opportunities for collaboration, accelerate innovation, and drive mutual economic growth.

Join us in shaping the future of engineering biology—where UK creativity meets Japan's world-class innovation ecosystem.



Chromatin Bioscience is a platform technology company developing chromatinLENS. Our platform integrates functional genomics data to design novel promoters for strong, cell-type-selective gene expression, improving the safety and efficacy of gene and cell therapies. Chromatin works with several companies, including Astellas, Johnson & Johnson and Orchard Therapeutics, with promoters already used in a clinical-stage in vivo CAR-T programme.



Dr Michael L Roberts
CEO

michael@chromatinbio.com



Dr Kostas Drosopoulos
Director of Business Development

kostas@chromatinbio.com



With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders for millions of patients around the world, Cumulus is advancing NeuLogiq®, an AI-based, multi-domain digital biomarker platform designed with 10 of the world's leading pharma companies to enable better, faster decision making in CNS clinical trials.



Tina Sampath
CEO

tina.sampath@cumulusneuro.com



Terry Reilly
SVP Business Development

terry.reilly@cumulusneuro.com



Re-Vana Therapeutics is a Belfast-based venture-backed therapeutics and drug delivery company developing proprietary sustained-release technologies for biologics, peptides, and small molecules. Its EyeLief® and OcuLief® platforms extend therapeutic durability, reducing treatment burden in retinal disease. With broad potential across ophthalmology, oncology, and other therapeutic areas, Re-Vana is advancing partnered and internal programmes, including a \$1 billion collaboration with Boehringer Ingelheim.



Hans Christinger
Chief Business Officer

h.christinger@revanatx.com



TauRx Pharmaceuticals Ltd has developed a potentially pioneering drug for Alzheimer's disease which is currently under regulatory review in the UK. A decision is expected in 2026, and if approved, the drug could become the world's first oral disease-modifying treatment for mild cognitive impairment. The company's proprietary discovery platform also supports design, synthesis and testing of next-generation tau-targeted therapeutics.



Prof. Claude Wischik
CEO & Chairman

cmw@taurx.com



Dr Glenn Corr
Chief Operating Officer and
Chief Business Officer
g.corr@taurx.com

Grow London Global Delegation

Grow London Global is a programme supported by the Mayor of London for the most innovative and fast-growing London-based companies looking to expand and collaborate internationally.

The Grow London Global programme now in its third year showcases London's most exciting scale-up companies across life sciences, green innovation, creative tech, fintech, and deep tech. This includes world-renowned names like Revolut, and Brompton Bicycles.

Since its launch, Grow London Global has supported over 2,200 companies, making it one of the largest and well-established of its kind globally.

Grow London Global offers each company expert commercial advice, sector focussed workshops, and events, as well as unrivalled networking opportunities to make valuable

contacts with corporates, non-profits organisations, academia, and investors across markets, globally.

The delegation visiting Japan this year is comprised of UK front runners in biotech & biopharma, digital health, and supply chain optimisation - the majority of whom are looking to raise further investment to bring their therapeutics and technologies to market to where it is needed most, but all of whom are looking to secure well aligned commercial and clinical partners in Japan and across APAC.

Rik Patel

Senior Trade Manager, Life Sciences

 Grow London

 Grow London

 grow.london

Grow London Global Delegation



Axiom Therapeutics is a London-based, Cambridge-founded drug discovery company using quantum-accurate physics and machine learning to design covalent medicines. We are progressing a pipeline in cancer and neurological disease, and partnering with pharma to accelerate their covalent discovery.

With a growing presence in Japan and China, we are seeking co-discovery partnerships and seed investment.



Ryan Geiser
CEO & Co-Founder

ryan@axiom-therapeutics.com



BioCorteX aims to help Asia's oncology assets become global blockbusters. Asia leads oncology innovation, yet in 83% of deals, outcomes fail to replicate. BioCorteX performs an 'in-silico bridge trial' in US populations, de-risking M&A for large pharma and providing key differentiation for biotechs. Our technology is based on fully transparent mechanisms rather than a 'black box' or AI approach.



Nikhil Sharma
CEO & Co-Founder

nik@biocortex.com

Grow London Global Delegation




Curenetics was founded to address the uncertainty immunotherapy decisions can bring for clinicians and patients. We developed CURE-IO, a proprietary AI-driven Cancer Immunotherapy Platform which utilises clinical data to predict patients' responses to immunotherapy with over 80% accuracy. This patient-centric solution would ensure the optimization of healthcare resources.



Dr Sola Adeleke
Founder & CEO

Sola@curenetics.io




deepmirror's foundation model, Elio, helps chemists design molecules with improved properties, accelerating the identification of preclinical candidates. More than 100 organisations have used the platform across 100+ programmes, repeatedly achieving tenfold property improvements in a single design cycle.



Max Jakobs
CEO

max@deepmirror.ai




Genomics is a techbio company leveraging genetic insights to advance population health and accelerate drug discovery using causal biology. Our research infrastructure, Mystra and Mystra AI, is powered by the largest harmonised multi-omic dataset and state-of-the-art analytics. While our polygenic risk assessment tools are used by leading global healthcare providers.



Michaela Broadhurst
Director of Corporate Development

michaela.broadhurst@genomics.com




iOWNA is a new healthcare operating system turning evidence-based guidance into guided patient journeys, much like Waze for driving. Clinicians set the destination, iOWNA guides patients to achieve it, improving outcomes, helping pharma extend support around their products, and helping health systems treat more patients efficiently.



Rupert Potter
Chief Commercial Officer

Rupert.potter@iowna.com





NEOBE
THERAPEUTICS

#Biotech
#DrugDelivery

Neobe is a preclinical startup using synthetic biology to engineer programmable microbes to permeabilize solid tumors, creating a permissive environment for curative responses to existing therapeutics. By locally removing fibrotic barriers to infiltration our products can function as universal APIs for cancer treatments, enabling responses to different forms of precision therapeutics.



**Pedro Correa
de Sampaio**
CEO

pedro@neobetherapeutics.com



neobetherapeutics.com



neobe-therapeutics



Panakeia

#diagnostics
#multiomics
#AI

Panakeia Technologies is a phenomics company delivering AI-based software platform solutions for profiling multi-omics biomarkers directly from H&E-stained slides for integrated precision drug discovery, development and clinical decision making.



Dr Pahini Pandya
Founder & CEO

pahini@panakeia.ai



panakeia



panakeia.ai



pear bio

#Biotech
#PrecisionMedicine

Pear Bio uses a functional precision medicine platform to create novel therapeutics for hard-to-treat cancers. Our lead program is a best-in-class CDK12 inhibitor in IND-enabling studies (first-in-human trials expected in H2 2026). We are interested in partnering and investment opportunities.



Duleek Ranatunga
CEO

duleek@pearbio.com



pearbio.com



pear-bio



PentaBind™

#TechBio
#DrugDiscovery

PentaBind is an AI-enabled aptamer therapeutics company combining proprietary computational design with closed-loop wet-lab discovery. Our platform generates up to 300 times more candidates, up to eight times faster, enabling partners to discover selective aptamers against closely related protein families, disease-specific proteoforms and challenging membrane targets.



Yashas Kannan
VP, Drug Discovery

yashas.kannan@pentabind.com



pentabind.com



pentabind



Contact us

Please get in touch to find out how we can help you grow your business in London and the UK, including:

- University/NHS research collaborations
- Evidence generation and regulatory guidance
- Commercialisation expertise
- Investment
- Finding lab space
- Community networking

For inward investment enquires, contact:
medcitycomms@londonandpartners.com
medcityhq.com
lifescience.london